Trial reportDiabetes, obesity & metabolism2026
Importance of targeting post-prandial hyperglycaemia to achieve HbA1c goals in insulin glargine-treated subphenotypes of type 2 diabetes.
Trial report in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Importance of targeting post-prandial hyperglycaemia to achieve HbA1c goals in insulin glargine-treated subphenotypes of type 2 diabetes.Diabetes, obesity & metabolism · 2026Trial
- Unnatural amino acid compounds as potent multi-target inhibitors of aldose reductase, α-glucosidase, and α-amylase: integrated in vitro, SAR, and molecular dynamics insights.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
aimsTo explore outcome parameters related to achieving HbA1c goal (<7.0%) in subphenotypes of type 2 diabetes (T2D), either on basal insulin (BI) glargine 300 U/mL or 100 U/mL or switched to these BIs (≥42 U/day) alone or with pre-prandial insulin. MATERIALS AND
methodsParticipants from three EDITION T2D trials (n = 2,435) were clustered into T2D subphenotypes, with ≥97% having either Severe Insulin-Deficient Diabetes (SIDD) (9%-22%), Mild Age-Related Diabetes (MARD) (8%-18%), or Mild Obesity Diabetes (MOD) (56%-78%) across trials. Subphenotypes were stratified by HbA1c goal achievement (HbA1c <7.0%/responders or ≥7.0%/non-responders), and efficacy and safety parameters were analysed both at baseline and after 26 weeks. Glargine groups were pooled.
resultsWith all basal insulin regimens, the responders were fewest in SIDD (19%-33%), followed by MOD (33%-56%) and MARD (42%-62%). Mean FPG at 26 weeks was slightly lower in responders (103-128 mg/dL; 5.8-7.1 mmol/L) compared to non-responders (124-143 mg/dL; 6.9-7.9 mmol/L) in each subphenotype, despite equivalent or higher mean glargine doses in non-responders. Self-monitored post-prandial glucose (PPG) was consistently above the recommended target of 140 mg/dL (7.8 mmol/L) in non-responders, even in those on intensified insulin treatment. Hypoglycaemia risk was similar or only slightly increased in responders compared to non-responders across subphenotypes.
conclusionsWith glargine-based regimens, strict control of PPG is necessary to attain HbA1c <7.0% across all T2D subphenotypes. Therefore, to achieve optimal treatment goals, especially in the SIDD subphenotype, appropriate dose adjustments of both basal and preprandial insulin are required.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.